Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like Biogen To Present Data At July 13, 2017 Recipharm to End Operations at Two Swedish Facilities, 225 Employees Affected November 8, 2017 Argenx Announces Full Exercise Of Underwriters' Option To Purchase Additional ADSs May 18, 2017
